Phase I trial of taxol given as a 3-hour infusion every 21 days.
about
A comparison of immunotoxic effects of nanomedicinal products with regulatory immunotoxicity testing requirementsFormulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular Mycobacterium avium infectionTaxol: an important new drug in the management of epithelial ovarian cancer.First line treatment of advanced non-small-cell lung cancer - specific focus on albumin bound paclitaxel.Taxanes: their impact on gynecologic malignancy.Taxol alleviates 2-methoxyestradiol-induced endothelial permeability.
P2860
Phase I trial of taxol given as a 3-hour infusion every 21 days.
description
1986 nî lūn-bûn
@nan
1986 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1986 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1986年の論文
@ja
1986年論文
@yue
1986年論文
@zh-hant
1986年論文
@zh-hk
1986年論文
@zh-mo
1986年論文
@zh-tw
1986年论文
@wuu
name
Phase I trial of taxol given as a 3-hour infusion every 21 days.
@ast
Phase I trial of taxol given as a 3-hour infusion every 21 days.
@en
type
label
Phase I trial of taxol given as a 3-hour infusion every 21 days.
@ast
Phase I trial of taxol given as a 3-hour infusion every 21 days.
@en
prefLabel
Phase I trial of taxol given as a 3-hour infusion every 21 days.
@ast
Phase I trial of taxol given as a 3-hour infusion every 21 days.
@en
P2093
P1476
Phase I trial of taxol given as a 3-hour infusion every 21 days.
@en
P2093
O'Connell JP
Parente RM
Wertheim MS
P304
P577
1986-05-01T00:00:00Z